A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.
Patients with moderate-to-severe asthma had significant reductions in annualized severe asthma exacerbation rate with the monoclonal antibody dupilumab, regardless of lung function, according to a post hoc analysis of LIBERTY ASTHMA QUEST* presented at ERS 2020.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Vitamin D therapy and bariatric surgery in obese asthmatic patients both improve peripheral blood mononuclear cells (PBMC) sensitivity to the in vitro corticosteroid (CS) treatment, results of a Spain study have shown.
Asthma manifests differently between patients from urban and rural areas, likely due in part to differing environments, according to a recent study presented at the virtual International Congress 2020 of the European Respiratory Society (ERS 2020).
In children with asthma, genotype testing identifies a specific genetic alteration associated with poor response to long-acting β2 agonist (LABA), as shown in the PACT trial. This information proves useful in prescribing appropriate medications and improving asthma control.
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.
Frequent coughing at night, measured using a smartphone app, appears to be a reliable indicator of worsening asthma, as reported in a study presented at this year’s European Respiratory Society (ERS) virtual meeting.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.